BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28673046)

  • 1. Generation and characterization of a monoclonal antibody to the cytoplasmic tail of MUC16.
    Gipson IK; Mandel U; Menon B; Michaud S; Tisdale A; Campos D; Clausen H
    Glycobiology; 2017 Oct; 27(10):920-926. PubMed ID: 28673046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation.
    Nemieboka B; Sharma SK; Rao TD; Edwards KJ; Yan S; Wang P; Ragupathi A; Piersigilli A; Spriggs DR; Lewis JS
    Nucl Med Biol; 2020; 86-87():9-19. PubMed ID: 32403071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer.
    Aithal A; Junker WM; Kshirsagar P; Das S; Kaur S; Orzechowski C; Gautam SK; Jahan R; Sheinin YM; Lakshmanan I; Ponnusamy MP; Batra SK; Jain M
    PLoS One; 2018; 13(4):e0193907. PubMed ID: 29708979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel monoclonal antibody to a defined peptide epitope in MUC16.
    Marcos-Silva L; Ricardo S; Chen K; Blixt O; Arigi E; Pereira D; Høgdall E; Mandel U; Bennett EP; Vakhrushev SY; David L; Clausen H
    Glycobiology; 2015 Nov; 25(11):1172-82. PubMed ID: 26201951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope.
    Argüeso P; Spurr-Michaud S; Russo CL; Tisdale A; Gipson IK
    Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2487-95. PubMed ID: 12766047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models.
    Chen Y; Clark S; Wong T; Chen Y; Chen Y; Dennis MS; Luis E; Zhong F; Bheddah S; Koeppen H; Gogineni A; Ross S; Polakis P; Mallet W
    Cancer Res; 2007 May; 67(10):4924-32. PubMed ID: 17510422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
    Felder M; Kapur A; Gonzalez-Bosquet J; Horibata S; Heintz J; Albrecht R; Fass L; Kaur J; Hu K; Shojaei H; Whelan RJ; Patankar MS
    Mol Cancer; 2014 May; 13():129. PubMed ID: 24886523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.
    Dharma Rao T; Park KJ; Smith-Jones P; Iasonos A; Linkov I; Soslow RA; Spriggs DR
    Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):462-72. PubMed ID: 20453816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transformation of NIH3T3 mouse fibroblast cells by MUC16 mucin (CA125) is driven by its cytoplasmic tail.
    Giannakouros P; Matte I; Rancourt C; Piché A
    Int J Oncol; 2015 Jan; 46(1):91-8. PubMed ID: 25338620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis.
    Thériault C; Pinard M; Comamala M; Migneault M; Beaudin J; Matte I; Boivin M; Piché A; Rancourt C
    Gynecol Oncol; 2011 Jun; 121(3):434-43. PubMed ID: 21421261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Release of membrane-associated mucins from ocular surface epithelia.
    Blalock TD; Spurr-Michaud SJ; Tisdale AS; Gipson IK
    Invest Ophthalmol Vis Sci; 2008 May; 49(5):1864-71. PubMed ID: 18436821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.
    Budiu RA; Mantia-Smaldone G; Elishaev E; Chu T; Thaller J; McCabe K; Lenzner D; Edwards RP; Vlad AM
    Cancer Immunol Immunother; 2011 Jul; 60(7):975-84. PubMed ID: 21461842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A biosensor for determination of the circulating biomarker CA125/MUC16 by Surface Plasmon Resonance Imaging.
    Szymańska B; Lukaszewski Z; Hermanowicz-Szamatowicz K; Gorodkiewicz E
    Talanta; 2020 Jan; 206():120187. PubMed ID: 31514860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of binding epitopes of CA125 monoclonal antibodies.
    Marcos-Silva L; Narimatsu Y; Halim A; Campos D; Yang Z; Tarp MA; Pereira PJ; Mandel U; Bennett EP; Vakhrushev SY; Levery SB; David L; Clausen H
    J Proteome Res; 2014 Jul; 13(7):3349-59. PubMed ID: 24850311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus-like particle vaccine displaying an external, membrane adjacent MUC16 epitope elicits ovarian cancer-reactive antibodies.
    Tu HF; Wong M; Tseng SH; Ingavat N; Olczak P; Notarte KI; Hung CF; Roden RBS
    J Ovarian Res; 2024 Jan; 17(1):19. PubMed ID: 38225646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MUC16 suppresses human and murine innate immune responses.
    Felder M; Kapur A; Rakhmilevich AL; Qu X; Sondel PM; Gillies SD; Connor J; Patankar MS
    Gynecol Oncol; 2019 Mar; 152(3):618-628. PubMed ID: 30626487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of a novel microscopic technique for quantifying CA125 binding to circulating mononuclear cells in longitudinal specimens during treatment for ovarian cancer.
    Lakatos K; González G; Hoballah J; Brooker J; Jeong S; Evans C; Krauledat P; Hansen WP; Elias KM; Patankar M; Fülöp V; Konstantinopoulos PA; Cramer DW
    J Ovarian Res; 2022 Feb; 15(1):28. PubMed ID: 35219339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
    Crawford A; Haber L; Kelly MP; Vazzana K; Canova L; Ram P; Pawashe A; Finney J; Jalal S; Chiu D; Colleton CA; Garnova E; Makonnen S; Hickey C; Krueger P; DelFino F; Potocky T; Kuhnert J; Godin S; Retter MW; Duramad P; MacDonald D; Olson WC; Fairhurst J; Huang T; Martin J; Lin JC; Smith E; Thurston G; Kirshner JR
    Sci Transl Med; 2019 Jun; 11(497):. PubMed ID: 31217340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells.
    Comamala M; Pinard M; Thériault C; Matte I; Albert A; Boivin M; Beaudin J; Piché A; Rancourt C
    Br J Cancer; 2011 Mar; 104(6):989-99. PubMed ID: 21326240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer.
    Mack KN; Samuels ZV; Carter LM; Viray TD; Mandleywala K; Brooks CL; Hollingsworth MA; Radhakrishnan P; Lewis JS
    J Nucl Med; 2024 Apr; 65(4):580-585. PubMed ID: 38485271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.